MarketResearchReports.Biz
announces addition of new report"
Bipolar Disorder - Japan Drug Forecast and Market Analysis to 2024
"to
its database.
Bipolar
disorder is a mental disorder characterized by periods of mania and
depression. The frequency, severity, and pattern of these episodes
can vary considerably over time and between individuals, making
bipolar disorder one of the most challenging psychiatric disorders to
manage. The bipolar disorder market is widely genericized, with
additional key brands expected to face patent or data exclusivity
expiries during the forecast period. The bipolar disorder market size
is anticipated to contract significantly between 2014 and 2024,
driven largely by the generic erosion of Otsukas Abilify, the highest
selling bipolar disorder product in 2014. The uptake of novel
atypical antipsychotic products will be a principal driver of growth
over the forecast period, as these products offer clinical advantages
that will drive strong uptake. However, sales of these agents will be
limited by the continued utilization of established generic products.
There are currently only two products in Phase III development, which
indicates that bipolar disorder will remain a field of high unmet
need during the forecast period.
GlobalData
estimates that drug sales for bipolar disorder in Japan reached
$373.4m during 2014, making it the second largest market within the
8MM. The market is expected to grow starting from 2020, driven by the
saturation of generic erosion and the uptake of novel pipeline
agents.
View Report At
:http://www.marketresearchreports.biz/analysis/735375
Scope
-
Overview of Bipolar Disorder including epidemiology, etiology,
symptoms, diagnosis, pathology and treatment guidelines as well as an
overview on the competitive landscape.
-
Detailed information on the key drugs in Japan including product
description, safety and efficacy profiles as well as a SWOT analysis.
-
Sales forecast for the top drugs in Japan from 2014-2024.
-
Analysis of the impact of key events as well the drivers and
restraints affecting Japan Bipolar Disorder market.
Reasons to buy
-
Understand and capitalize by identifying products that are most
likely to ensure a robust return
-
Stay ahead of the competition by understanding the changing
competitive landscape for Bipolar Disorder.
-
Effectively plan your M&A and partnership strategies by
identifying drugs with the most promising sales potential
-
Make more informed business decisions from insightful and in-depth
analysis of drug performance
-
Obtain sales forecast for drugs from 2014-2024 in Japan.
Download Sample copy of this
Report at
Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Related Reports
3 Disease Overview
3.1 Etiology and
Pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.2 Classification
3.3 Symptoms
3.4 Prognosis
4 Disease Management
4.1 Diagnosis Overview
4.1.1 Clinical Evaluation
4.1.2 Screening Tools
4.2 Treatment Overview
4.2.1 Treatment Initiation and
Maintenance Therapy
4.2.2 Manic or Mixed Episodes
4.2.3 Acute Agitation
4.2.4 Hypomanic Episodes
4.2.5 Major Depressive Episodes
4.2.6 Rapid Cycling
4.2.7 Cyclothymia
4.2.8 Other Treatment Factors
4.3 Treatment Guidelines and
Leading Prescribed Drugs
4.4 Japan
5 Competitive Assessment
5.1 Overview
5.2 Product Profiles - Major
Brands
5.2.1 Lithium
5.2.2 Anticonvulsants
About us
MarketResearchReports.biz
is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Contact
Mr.
Nachiket
State Tower
90
Sate Street, Suite 700
Albany,
NY 12207
Tel:
+1-518-621-2074
No comments:
Post a Comment